[1]
|
Horoszewicz, J.S., Kawinski, E. and Murphy, G.P. (1987) Monoclonal Antibodies to a New Antigenic Marker in Epi-thelial Prostatic Cells and Serum of Prostatic Cancer Patients. Anticancer Research, 7, 927-935.
|
[2]
|
Ghosh, A. and Heston, W.D.W. (2004) Tumor Target Prostate Specific Membrane Antigen (PSMA) and Its Regulation in Prostate Cancer. Journal of Cellular Biochemistry, 91, 528-539. https://doi.org/10.1002/jcb.10661
|
[3]
|
Chang, S.S., Gaudin, P.B., Reuter, V.E. and Heston, W.D.W. (2000) Prostate-Specific Membrane Antigen: Present and Future Applications. Urology, 55, 622-629. https://doi.org/10.1016/S0090-4295(99)00600-7
|
[4]
|
Yao, V. and Bacich, D.J. (2006) Prostate Specific Membrane Antigen (PSMA) Expression Gives Prostate Cancer Cells a Growth Advantage in a Physiologically Relevant Folate Environment in Vitro. The Prostate, 66, 867-875.
https://doi.org/10.1002/pros.20361
|
[5]
|
Yao, V., Berkman, C.E., Choi, J.K., O’Keefe, D.S. and Bacich, D.J. (2010) Expression of Prostate-Specific Membrane Antigen (PSMA), Increases Cell Folate Uptake and Proliferation and Suggests a Novel Role for PSMA in the Uptake of the Non-Polyglutamated Folate, Folicacid. The Prostate, 70, 305-316. https://doi.org/10.1002/pros.21065
|
[6]
|
Zhang, Y., Guo, Z., Du, T., Chen, J., Wang, W., Xu, K., et al. (2013) Prostate Specific Membrane Antigen (PSMA): A Novel Modulator of p38 for Proliferation, Migration, and Survival in Prostate Cancer Cells. The Prostate, 73, 835-841.
https://doi.org/10.1002/pros.22627
|
[7]
|
Guo, Z., Lai, Y., Du, T., Zhang, Y., Chen, J., Bi, L., et al. (2014) Prostate Specific Membrane Antigen Knockdown Impairs the Tumorigenicity of LNCaP Prostate Cancer Cells by Inhibiting the Phosphatidylinositol 3-Kinase/Akt Signaling Pathway. Chinese Medical Journal, 127, 929-936.
|
[8]
|
Xu, L., Wang, Z., Li, X.-F., He, X., Guan, L.-L., Tuo, J.-L., et al. (2013) Screening and Identification of Significant Genes Related to Tumor Metastasis and PSMA in Prostate Cancer Using Microarray Analysis. Oncology Reports, 30, 1920-1928. https://doi.org/10.3892/or.2013.2656
|
[9]
|
Miyahira, A.K., Pienta, K.J., Morris, M.J., Bander, N.H., Baum, R.P., Fendler, W.P., et al. (2018) Meeting Report from the Prostate Cancer Foundation PSMA-Directed Radionuclide Scien-tific Working Group. The Prostate, 78, 775-789.
https://doi.org/10.1002/pros.23642
|
[10]
|
Fanti, S., Minozzi, S., Antoch, G., Banks, I., Briganti, A., Carrio, I., et al. (2018) Consensus on Molecular Imaging and Theranostics in Prostate Cancer. The Lancet Oncology, 19, e696-e708. https://doi.org/10.1016/S1470-2045(18)30604-1
|
[11]
|
Fendler, W.P., Schmidt, D.F., Wenter, V., Thierfelder, K.M., Zach, C., Stief, C., et al. (2016) 68GaPSMA PET/CT Detects the Location and Extent of Primary Prostate Cancer. Journal of Nuclear Medicine, 57, 1720-1725.
https://doi.org/10.2967/jnumed.116.172627
|
[12]
|
Woythal, N., Arsenic, R., Kempkensteffen, C., Miller, K., Janssen, J.C., Huang, K., et al. (2018) Immunohistochemical Validation of PSMA Expression Measured by 68Ga-PSMA PET/CT in Primary Prostate Cancer. Journal of Nuclear Medicine, 59, 238-243. https://doi.org/10.2967/jnumed.117.195172
|
[13]
|
Uprimny, C., Kroiss, A.S., Decristoforo, C., Fritz, J., von Gug-genberg, E., Kendler, D., et al. (2017) 68Ga-PSMA-11 PET/CT in Primary Staging of Prostate Cancer: PSA and Gleason Score Predict the Intensity of Tracer Accumulation in the Primary Tumour. European Journal of Nuclear Medicine and Molecular Imaging, 44, 941-949.
https://doi.org/10.1007/s00259-017-3631-6
|
[14]
|
Mottet, N., Bellmunt, J., Bolla, M., Briers, E., Cumberbatch, M.G., De Santis, M., et al. (2017) EAU-ESTROSIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. European Urology, 71, 618-629. https://doi.org/10.1016/j.eururo.2016.08.003
|
[15]
|
van Leeuwen, P.J., Emmett, L., Ho, B., Delprado, W., Ting, F., Nguyen, Q. and Stricker, P.D. (2017) Prospective Evaluation of 68Gallium-Prostate-Specific Membrane Antigen Posi-tron Emission Tomography/Computed Tomography for Preoperative Lymph Node Staging in Prostate Cancer. Uro-logical Oncology, 119, 209-215.
https://doi.org/10.1111/bju.13540
|
[16]
|
Gorin, M.A., Rowe, S.P., Patel, H.D., Vidal, I., Mana-Ay, M., Javadi, M.S., et al. (2018) Prostate Specific Membrane Antigen Targeted 18F-DCFPyL Positron Emission Tomography/Computerized Tomography for the Preoperative Staging of High Risk Prostate Cancer: Results of a Prospective, Phase II, Single Center Study. Journal of Urology, 199, 126-132. https://doi.org/10.1016/j.juro.2017.07.070
|
[17]
|
Maurer, T., Gschwend, J.E., Rauscher, I., Souvatzoglou, M., Haller, B., Weirich, G., et al. (2016) Diagnostic Efficacy of 68Gallium-PSMA Positron Emission Tomography Compared to Conventional Imaging for Lymph Node Staging of 130 Consecutive Patients with Intermediate to High Risk Prostate Cancer. Journal of Urology, 195, 1436-1443.
https://doi.org/10.1016/j.juro.2015.12.025
|
[18]
|
Ireson, C.R. and Kelland, L.R. (2006) Discovery and Development of Anticancer Aptamers. Molecular Cancer Therapeutics, 5, 2957-2962. https://doi.org/10.1158/1535-7163.MCT-06-0172
|
[19]
|
Lupold, S.E., Hicke, B.J., Lin, Y. and Coffey, D.S. (2002) Identification and Characterization of Nuclease-Stabilized RNA Molecules that Bind Human Prostate Cancer Cells via the Prostate-Specific Membrane Antigen. Cancer Research, 62, 4029-4033.
|
[20]
|
Xu, W., Siddiqui, I.A., Nihal, M., Pilla, S., Rosenthal, K., Mukhtar, H., et al. (2013) Aptamer-Conjugated and Doxorubicin-Loaded Unimolecular Micelles for Targeted Therapy of Prostate Cancer. Biomaterials, 34, 5244-5253.
https://doi.org/10.1016/j.biomaterials.2013.03.006
|
[21]
|
Wang, X., Ma, D., Olson, W.C. and Heston, W.D.W. (2011) In Vitro and in Vivo Responses of Advanced Prostate Tumors to PSMA ADC, an Auristatin-Conjugated Anti-body to Prostate-Specific Membrane Antigen. Molecular Cancer Therapeutics, 10, 1728-1739. https://doi.org/10.1158/1535-7163.MCT-11-0191
|
[22]
|
Petrylak, D.P., Smith, D.C., Appleman, L.J., Fleming, M.T., Hussain, A., Dreicer, R., et al. (2014) A Phase 2 Trial of Prostate-Specific Membrane Antigen Antibody Drug Conjugate (PSMA ADC) in Taxane-Refractory Metastatic Castration-Resistant Prostate Cancer (mCRPC). Journal of Clinical Oncology, 32, 5023-5023.
https://doi.org/10.1200/jco.2014.32.15_suppl.5023
|
[23]
|
Denmeade, S.R., Mhaka, A.M., Rosen, D.M., Brennen, W.N., Dalrymple, S., Dach, I., et al. (2012) Engineering a Prostate-Specific Membrane Antigen-Activated Tumor En-dothelial Cell Prodrug for Cancer Therapy. Science Translational Medicine, 4, 140ra86. https://doi.org/10.1126/scitranslmed.3003886
|
[24]
|
Ma, Q., Safar, M., Holmes, E., Wang, Y., Boynton, A.L. and Junghans, R.P. (2004) Anti-Prostate Specific Membrane Antigen Designer T Cells for Prostate Cancer Therapy. The Prostate, 61, 12-25. https://doi.org/10.1002/pros.20073
|
[25]
|
Sugimoto, Y., Hirota, M., Yoshikawa, K., Sumitomo, M., Nakamura, K., Ueda, R., et al. (2014) The Therapeutic Potential of a Novel PSMA Antibody and Its IL-2 Conjugate in Prostate Cancer. Anticancer Research, 34, 89-97.
|
[26]
|
Yeku, O. and Slovin, S.F. (2016) Immune Therapy for Prostate Cancer. The Cancer Journal, 22, 334-341.
https://doi.org/10.1097/PPO.0000000000000223
|
[27]
|
Bandekar, A., Zhu, C., Jindal, R., Bruchertseifer, F., Mor-genstern, A. and Sofou, S. (2014) Anti-Prostate-Specific Membrane Antigen Liposomes Loaded with 225Ac for Poten-tial Targeted Antivascular α-Particle Therapy of Cancer. Journal of Nuclear Medicine, 55, 107-114. https://doi.org/10.2967/jnumed.113.125476
|